RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

Editorial

Issue 44
Securting quality cancer care:  Governments must step up to the plate
Issue 43
Patients need information.  Is that clear?
Issue 42
Adapting services to the age of oral therapies
Issue 41
A million voices against cancer
Issue 40
Our role in moulding the image of cancer
Issue 39
Fake drugs pose a threat to Europe's cancer patients
Issue 38
Is it safe, is it tolerable? Why not ask the patients?
Issue 37
Turning the World Cancer Declaration into action
Issue 36
When the trial you need is just over the border
Issue 35
Stop excluding male patients
Issue 34
A partnership with potential
Issue 33
Rare cancers in Europe - tacking a common problem
Issue 32
Talking the same language
Issue 31
Prostate cancer screening: a question of common sense
Issue 30
It's about living, not just surviving
Issue 29
Europe's nurses: an untapped resource 
Issue 28
Senior, elderly, geriatric: we are all getting older 
Issue 27
A window of opportunity 
Issue 26
ECCO–ESMO: a powerful partnership 
Issue 25
A question of human dignity 
Issue 24
Shameful statistics of pain 
Issue 23
Diet and exercise: it's time to act on the evidence 
Issue 22
Men's health matters too 
Issue 21
Tackling the adherence crisis 
Issue 20
Passing on the baton 
Issue 19
Our responsability to survivors 
Issue 18
Elderly patients deserve better 
Issue 17
The challege for St Gallen 
Issue 16
A question of public trust 
Issue 15
The write stuff 
Issue 14
Making rights a reality 
Issue 13
UICC - taking on mission impossible 
Issue 12
Getting serious about e-qual @ccess 
Issue 11
We don't have to be a year behind
Issue 10
Hope or hype? 
Issue 9
A European report card 
Issue 8
A stronger voice within Europe 
Issue 7
A quiet revolution 
Issue 6
Balancing safety against need 
Issue 5
The power of words 
Issue 4
End this secrecy over clinical trials 
Issue 3
Too valuable to put a price on 
Issue 2
Our partnership with patients 
Issue 1
Welcome to our World 

 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR16 - Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists (based on a review article of Critical Reviews in Oncology Hematology)

GR182 - Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

GR183 - The current management of low-grade glioma in childhood

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.